1. Home
  2. IFRX vs NA Comparison

IFRX vs NA Comparison

Compare IFRX & NA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$2.11

Market Cap

66.0M

Sector

Health Care

ML Signal

HOLD

NA

Nano Labs Ltd

HOLD

Current Price

$1.82

Market Cap

55.9M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
IFRX
NA
Founded
2007
2019
Country
Germany
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
66.0M
55.9M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
IFRX
NA
Price
$2.11
$1.82
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$6.25
N/A
AVG Volume (30 Days)
1.4M
80.1K
Earning Date
05-07-2026
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.71
$1.58
52 Week High
$2.20
$31.48

Technical Indicators

Market Signals
Indicator
IFRX
NA
Relative Strength Index (RSI) 81.36 31.25
Support Level $0.86 N/A
Resistance Level N/A $3.35
Average True Range (ATR) 0.22 0.29
MACD 0.07 -0.09
Stochastic Oscillator 90.31 14.24

Price Performance

Historical Comparison
IFRX
NA

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About NA Nano Labs Ltd

Nano Labs Ltd is a Web 3.0 infrastructure and product solution provider, as well as a crypto treasury company. It is focused on the development of HTC chips and HPC chips. In addition, the company has established BNB value investment and adopted BNB (a crypto token) as the primary reserve asset. Furthermore, it has launched the iPollo Claw, a dedicated hardware solution for the OpenClaw AI Agent Ecosystem. Nano Labs derives revenue mainly from its HTC and HPC offerings, which comprise Darkbird series HPC chips that feature high performance and high energy consumption efficiency, and Cuckoo series chips, used in GPUs. Geographically, the company generates maximum revenue from the People's Republic of China (PRC), and the rest from Singapore, Hong Kong, the United States, and other markets.

Share on Social Networks: